Severe Morbidity and Mortality Risk From
Malaria in the United States, 1985–2011 by Hwang, Jimee et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Public Health Resources Public Health Resources
2014
Severe Morbidity and Mortality Risk From Malaria
in the United States, 1985–2011
Jimee Hwang
Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia
Karen A. Cullen
Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia
S. Patrick Kachur
Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia
Paul M. Arguin
Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia
J. Kevin Baird
Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia, jkevinbaird@yahoo.com
Follow this and additional works at: http://digitalcommons.unl.edu/publichealthresources
This Article is brought to you for free and open access by the Public Health Resources at DigitalCommons@University of Nebraska - Lincoln. It has
been accepted for inclusion in Public Health Resources by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
Hwang, Jimee; Cullen, Karen A.; Kachur, S. Patrick; Arguin, Paul M.; and Baird, J. Kevin, "Severe Morbidity and Mortality Risk From
Malaria in the United States, 1985–2011" (2014). Public Health Resources. 373.
http://digitalcommons.unl.edu/publichealthresources/373
M A J O R A R T I C L E
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Malaria in the United States, 1985–2011
Jimee Hwang,1,2 Karen A. Cullen,1 S. Patrick Kachur,1 Paul M. Arguin,1 and J. Kevin Baird3,4
1Malaria Branch, Centers for Disease Control and Prevention, Atlanta, Georgia; 2Global Health Group, University of California, San Francisco, California;
3Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia; and 4Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford,
United Kingdom
Background. Recent reports of Plasmodium vivax associated with severe syndromes and mortality from malaria
endemic areas questions the “benign” course of non-falciparum malarias.
Methods. We retrospectively analyzed data from patients reported to the US Centers for Disease Control and
Prevention with a diagnosis of malaria parasite single-species infection between 1985 and 2011. Patients classified as
having severe illness were further classified according to outcome (survival versus death) and clinical syndrome.
Results. Among all cases, .9% of Plasmodium falciparum cases resulted in death and 9.3% were classified as
severe, whereas .09% of P. vivax cases resulted in death and 1.3% were classified as severe. The odds ratios for severe
illness among 15 272 diagnoses of P. falciparum relative to patients diagnosed with P. vivax (n = 12 152), Plasmodium
malariae (n = 1254), or Plasmodium ovale (n = 903) was 7.5, 5.7, and 5.0, respectively (P < .0001 for all); in contrast,
the corresponding odds ratios for death among those severely ill was 1.6, 1.1, and .8 (P > .1 for all), respectively. Com-
pared with P. vivax (n = 163), the odds of P. falciparum cases classified as severely ill (n = 1416) were 1.9 (P = .0006),
.5 (P = .001), and 1.3 times (P = .1) as likely to present as cerebral, acute respiratory distress, and renal syndromes,
respectively.
Conclusions. Although less common, patients presenting with non-falciparum even in the United States can devel-
op severe illness, and severe illness in patients having malaria of any species threatens life.
Keywords. morbidity; mortality; Plasmodium; species; USA.
The medical, scientific, and public health communities
have long considered a diagnosis of malaria caused
by Plasmodium vivax, Plasmodium malariae, or Plas-
modium ovale rarely threatening to life. In contrast,
Plasmodium falciparum is acknowledged as often life
threatening. This difference is the basis of the widely ap-
plied clinical division of falciparum and non-falciparum
malarias as representing malignant versus benign ma-
larias. That dichotomy effectively defines not only
how the global malaria problem is perceived and
managed [1], but also influences strategies of prevention
and treatment in individual patients. The perception of
P. vivax as generally harmless with respect to mortality
risk effectively fostered its neglect in research and public
health for over six decades [2], despite heavy burdens of
risk and disease [3].
Over the past decade, case reports and hospital- and
village-based studies in endemic zones demonstrate that
P. vivax often results in serious illness and fatal out-
comes. Summarizing these studies, approximately
10%–20% of admissions with a primary diagnosis of
P. falciparum or P. vivax were classified as severe, and
approximately 5%–15% of those did not survive [1].
Both species appeared to be associated with significant
risk of severe morbidity and mortality among hospital-
ized patients. Falciparum and vivax malarias were
equally threatening to children in one village in Papua
New Guinea [4] and to pregnant women and their fe-
tuses in Indonesia and Thailand [5–7]. Historic experi-
ence with malaria therapy applying P. vivax in otherwise
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relatively healthy neurosyphilis patients resulted in a 5%–15% risk
of mortality, and this result also refuted its benign identity [1].
In 2011, the largest number of cases of malaria since 1971
was reported to the US Centers for Disease Control and Preven-
tion (CDC) from healthcare providers within the United States.
Despite the apparent progress in reducing the number of malar-
ia cases in regions that are endemic for malaria, international
travel seems to be growing steadily, and use of appropriate pre-
vention measures by travelers remains inadequate [8]. Plasmo-
dium falciparum and P. vivax overwhelmingly dominate
estimated global populations at risk and likely case burdens
[3, 9–11]. The relative proportion among cases reported to the
CDC reflect the global codominance of these two species over
the other two, P. malariae and P. ovale [8].
Malaria incidence among travelers may be quite distinct
compared with patients living in endemic zones in very impor-
tant clinical, epidemiological, demographic, and socioeconomic
respects [12, 13]. Nonetheless, malaria among travelers and en-
demic country residents share the same etiologic agents and
their innate biological characteristics, including pathogenicity.
Lacking the naturally acquired partial immunity to acute malar-
ia common in endemic zones, nonimmune travelers who con-
tract malaria for the first time are less likely to be protected from
the innate pathogenic effects of the plasmodium species. On the
other hand, travelers usually have greater access to higher levels
of care compared with residents of endemic zones, but they may
experience delays in malaria diagnosis and treatment due to the
relative rarity of the infection.
After acknowledging these important confounding factors
with regard to clinical consequence of malaria infection, we un-
dertook an assessment of severe morbidity and mortality in
travelers diagnosed with malaria during the 27 years from
1985 to 2011 in the United States. In particular, we aimed at
evaluating the association between vivax malaria and severe ill-
ness and malaria mortality.
METHODS
Deidentified data from the US National Malaria Surveillance
System (NMSS) from 1985 to 2011 were used in this analysis
and have been described elsewhere [8]. In brief, malaria cases
diagnosed by blood film, polymerase chain reaction, or rapid di-
agnostic tests are mandated to be reported to local and state
health departments by healthcare providers or laboratory staff.
Case investigations are conducted by local and state health de-
partments, and reports are transmitted to CDC through the
NMSS or through direct CDC consults. Malaria cases were cat-
egorized by infecting species: P. falciparum, P. vivax, P. malar-
iae, and P. ovale. Cases infected with more than one species,
typically referred to as mixed infections, were rare and not in-
cluded in this analysis. In addition, cases where the species was
not reported were not included in the main analyses. The
zoonotic malaria from Southeast Asian macaques caused by
Plasmodium knowlesi [15] has been reported only once in a re-
turning traveler in the United States [16] and is not considered
in the current analysis. Although species confirmatory services
are available at the state and federal levels, most cases are not
confirmed and species confirmation is usually only sought in
nonplausible scenarios, eg, P. vivax acquired in Haiti.
Cases of severemalaria were defined as thosewith one ormore
of the following manifestations: death, neurologic symptoms,
renal failure, severe anemia, acute respiratory distress syndrome
(ARDS), jaundice, or ≥5% parasitemia. To attempt to include
severe cases in which clinical criteria were not reported, persons
who received a regimen recommended for the treatment of se-
vere malaria (ie, parenteral artesunate or quinidine, and/or an
exchange blood transfusion) despite having no specific severe
manifestations reported also were counted as a severe case in
this analysis. Neurologic symptoms or cerebral complications
were defined as impaired consciousness, coma, or repeated gen-
eralized convulsions. For surveillance purposes, severe illness is
categorized by CDC and not by the treating physician. In 2008,
CDC revised the case report form to collect information on par-
asitemia density, treatment with artesunate, quinine or quinidine,
and modified the anemia classification [17]. The anemia compli-
cation before 2008 was for those with hemoglobin (Hb) < 11 g/dL
and hematocrit < 33%. Beginning in 2008, severe anemia was de-
fined as Hb < 7 g/dL to be in line with the World Health Organi-
zation definition for severe cases. Beginning in 2010, CDC
established a partnership with the Armed Forces Health Surveil-
lance Center to identify additional cases occurring among mili-
tary personnel that might not have been identified previously
by local or state health departments or private healthcare provid-
ers [18]. Odds ratios (ORs) and 95% confidence intervals (CIs)
were calculated using SAS version 9.3 (Cary, NC). P values
< .05 were considered statistically significant.
With the varying number of cases with unknown species, a
sensitivity analysis was performed to assess the impact of pos-
sible misclassification of these cases on the prevalence of severe
malaria. The percentage of cases that were classified as being
severe was recalculated for P. falciparum and for P. vivax
under the assumption that all of the unknown cases were severe
P. falciparum or P. vivax, respectively, to determine the range of
possible ORs. In addition, to assess the differential impact of
hyperparasitemia (>5%), which more commonly occurs with
P. falciparum, the analyses were repeated excluding cases of
severe malaria due to hyperparasitemia alone without another
accompanying severe clinical syndrome.
RESULTS
All Cases: 1985–2011
Figure 1 illustrates the total annual number of cases of malaria
by species (excluding the 226 mixed infections and 5408 species
2 • OFID • Hwang et al
not reported; averaging 8 and 200 cases per year, respectively)
from 1985 through 2011. During 1985–1998, P. falciparum
and P. vivax contributed roughly equal halves to total case num-
bers. However, since 1999, P. falciparum cases have increased
substantially relative to P. vivax. Of note, the number of cases
with no species data also steadily increased during this period
(range, 50–575). During 2010 and 2011, reported cases of
both species increased substantially due to a concerted effort
to improve the completeness of reporting. Numbers of reported
cases involving the two minority species, P. malariae and P.
ovale, and mixed infections remained relatively constant over
these years.
Table 1 lists the numbers of cases classified as severe versus
not for P. falciparum and P. vivax over the period 1985–2011.
Of all cases, 122 of 13 971 (0.9%) of P. falciparum cases resulted
in death compared with 10 of 11 456 (0.09%) of P. vivax cases
(OR = 10.08; 95% CI = 5.29–19.22; P < .0001), and a diagnosis
of P. falciparum was more likely to be classified as severe relative
to that of P. vivax (OR = 7.5; 95% CI = 6.33–8.79; P < .0001). In
all, 9.3% of P. falciparum patients versus 1.3% of P. vivax
patients were classified as severely ill. Risk of death amongst
the severely ill (8.6% vs 6.1%, respectively) was not significantly
different (OR = 1.6; 95% CI = .82–3.12; P = .1649) between
P. falciparum and P. vivax. Patients with a diagnosis of
P. falciparum were slightly more likely to have cerebral complica-
tions compared with patients with a diagnosis of P. vivax
(OR = 1.9; 95% CI = 1.32–2.84; P = .0006). In contrast, severely
ill patients with a diagnosis of P. falciparum were less likely to ex-
perience ARDS (OR = .5; 95% CI = .35–.78; P = .0013) compared
with patients with P. vivax. There was no statistical difference for
renal complications (OR = 1.3; 95% CI = .93–1.88; P = .1235).
Excluding cases classified as severe based on hyperparasitemia
alone from the analysis did not significantly change the findings
that P. falciparum was more likely to cause severe disease com-
pared to P. vivax (OR = 1.9; 95% CI = 1.32–2.84; P = .0006). Like-
wise, the risk of death (OR = 1.6; 95% CI = .82–3.13; P = .1619),
cerebral malaria (OR = 1.97; 95% CI = 1.34–2.88; P = .0004),
ARDS (OR = .52; 95% CI = .35–.78; P = .0015), and renal failure
(OR = 1.34; 95% CI = .94–1.90; P = .1098) in those with severe ill-
ness remained essentially unchanged.
Table 1 also lists the same statistical summaries for diagnoses
of P. malariae and P. ovale compared with P. falciparum. Sim-
ilarly, P. malariae and P. ovale resulted in fewer deaths overall
than P. falciparum. Apart from risk of a classification of severe
disease for falciparum malaria relative to these malarias
(OR = 5.7; 95% CI = 3.74–8.75; P < .0001 for P. falciparum vs
Figure 1. Annual number of cases of malaria reported in the United States from 1985 to 2011, by species.
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P. malariae and OR = 5.0; 95% CI = 3.14–8.04; P < .0001 for
P. falciparum vs P. ovale), no significant differences appeared
for risk of death, cerebral malaria, ARDS, or renal failure for
either species diagnosis. The relatively few cases of these spe-
cies (n = 1254 for P. malariae and n = 903 for P. ovale), along
with relatively low frequencies of severe illness (1.8% and
2.0%), resulted in poor statistical power to analyze relative
risk of specific severe disease syndromes. Nonetheless, the
OR for death among cases with severe illness for P. falciparum
relative to that of P. malariae or P. ovale were 1.1 (95%
CI = .26–4.84; P = .8812) and .8 (95% CI = .19–3.71, P = .8165),
respectively.
Cases 2008–2011
Limiting the analysis to the time period using current surveil-
lance forms and improved reporting completeness, the years
2008–2011 were analyzed separately. Figure 2 illustrates the an-
nual proportion of patients classified as having severe illness
with a diagnosis of P. falciparum or P. vivax. Before 2008,
fewer than 10% and 5% of cases having these respective diag-
noses were classified as severely ill. Since that year, these rates
rose sharply to 21% and 7%, respectively, by 2011. This sharp
rise, although less notable, nonetheless persists if P. vivax or
P. falciparum were imputed with equal probability in all cases
without a species diagnosis. Figure 3 illustrates the relative pro-
portions of severe illness among cases of falciparum and the other
species [P. vivax (OR = .3; 95% CI = .20–.34; P < .0001); P. malar-
iae (OR = .4; 95% CI = .21–.73; P = .0024); P. ovale (OR = .4; 95%
CI = .19–.71; P = .0019)] during this period. Data for severe ane-
mia were only available from 2008 to 2011. There was no statis-
tical difference for severe anemia among patients classified
as severely ill with a diagnosis of falciparum versus vivax
(OR = .9; 95% CI = .50–1.66; P = .7512) or ovale malaria
(OR = .75; 95% CI = .19–2.95; P = .6828) (Table 1). Severe anemia
amongst those severely ill was less common with P. falciparum
than P. malariae (OR = .3; 95% CI = .08–.89; P = .0222).
Severe Illness OR Trend, 1985–2011
Figure 4 illustrates the OR for severe illness with a diagnosis of
P. falciparum relative to P. vivax for each year from 1985 to 2011
as well as the number of severe cases. Excluding rare outliers,
during 1985 to 2003, the annual ORs ranged from approximately
Table 1. Severe Morbidity and Mortality With a Diagnosis of Plasmodium falciparum Relative to That of Plasmodium vivax, Plasmodium
malariae, and Plasmodium ovale Among Travelers Presenting in the United States, 1985–2011
Syndrome*
P. falciparum P. vivax P. falciparum vs P. vivax
Syndrome (+) Syndrome (−) % Syndrome (+) Syndrome (−) % OR 95% CI P value
Fatal among all cases† 122 13 849 0.9% 10 11 446 0.09% 10.08 5.29, 19.22 <.0001
Severe 1416 13 856 9.3% 163 11 989 1.3% 7.46 6.33, 8.79 <.0001
Fatal† 122 1091 8.6% 10 143 6.1% 1.60 .82, 3.12 .1649
Cerebral malaria 514 902 36.3% 37 126 22.7% 1.94 1.32, 2.84 .0006
ARDS 176 1240 12.4% 35 128 21.5% .52 .35, .78 .0013
Renal 503 913 35.5% 48 115 29.4% 1.32 .93, 1.88 .1235
Severe anemia‡ 140 434 24.4% 16 45 26.2% .91 .50, 1.66 .7512
Syndrome*








(−) % OR 95% CI P Value
Fatal among
all cases†
2 1195 0.2% 5.26 1.30, 21.31 .0092 2 807 0.3% 3.55 .88, 14.40 .0577
Severe 22 1232 1.8% 5.72 3.74, 8.75 <.0001 18 885 2.0% 5.02 3.14, 8.04 <.0001
Fatal† 2 20 9.1% 1.12 .26, 4.84 .8812 2 15 11.8% .84 .19, 3.71 .8165
Cerebral
malaria
4 18 18.2% 2.56 .86, 7.62 .0791 2 16 11.1% 4.56 1.04, 19.91 .0270
ARDS 1 21 4.5% 1.25 .40, 22.30 .2642 2 16 11.1% 1.14 .26, 4.98 .8662
Renal 6 16 27.3% 1.47 .57, 3.78 .4221 7 11 38.9% .87 .33, 2.25 .7670
Severe
anemia‡
6 5 54.5% .27 .08, .89 .0222 3 7 30.0% .75 .19, 2.95 .6828
Abbreviations: ARDS, acute respiratory distress syndrome; CI, confidence interval; OR, odds ratio.
*The total number of cases do not sum to the total number of severe cases due to missing outcome data.
†Cases could have more than one syndrome or clinical complication in the course of their illness, thus the number of cases that are syndrome (+) do not sum to the
total classified as severe. Analyses of individual syndromes are among those who are classified as having severe disease.
‡2008–2011 reporting only.
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four to 15, but during 2004 to 2011 this number typically ranged
between three and four. Although the OR has trended down-
wards, these trends should be interpreted with caution because
reporting format and quality varied during this time period.
DISCUSSION
P. vivax has been increasingly reported as an important cause
of severe disease syndromes. When we analyzed all 29 489
single-species cases reported to the US CDC from 1985 to
2011, P. falciparum was ten times as likely to cause death and
seven times as likely to be classified as severe compared with
P. vivax. However, among the severely ill, the odds of death
were not significantly different (8.6% and 6.1%; P = .1649)
between the two species. Moreover, the odds of being classified
as severely ill with a diagnosis of P. falciparum relative to
P. vivax during 2008–2011, a period of improved data quality
and reporting coverage, fell sharply to an OR of 3.8
(P < .0001). In 2008, the US CDC began applying substantially
modified case detection, reporting, and illness classification al-
gorithms (see METHODS). We consider those changes very
probably responsible for the sharp increases in the proportion
of reported cases classified as severe (see Figure 2). The greater
sensitivity of the now current methods for detection and
classification of severe illness, however, applied equally to all
species of diagnosis. Therefore, these changes to surveillance
methods were unlikely to have confounded the measured
risks of severe illness with a diagnosis of one species relative
to another in any given year between 2008 and 2011. Compar-
isons of trends across years, especially before and after 2008,
should be interpreted with caution. We do not conclude, for ex-
ample, the rising odds of severe illness in P. vivax relative to P.
falciparum as evidence of increasingly threatening parasite
behavior.
The downward trend in OR for risk of severe illness with P.
falciparum versus P. vivax (see Figure 4) seems to be driven by
other factors. These factors could include changes to the report-
ing form as well as increased provider awareness of the severe
complications possible with P. vivax illness. Although rising re-
sistance to chloroquine by P. vivaxmay also be a factor [19], this
phenomenon has not been seen thus far as a common problem
in the management of post-travel vivax malaria in the United
States. Furthermore, pernicious virulence in P. vivax had been
evident in neurosyphilis patients treated with repeated severe
paroxysms of vivax malaria during the 1920s and 1930s [1].
The character and frequency of severe morbidity and mortality
in those patients was essentially similar to that in hospitalized
patients in endemic zones today—typically manifest as severe
Figure 2. Percentage of Plasmodium falciparum and P. vivax cases reported in the United States classified as severe, 1985–2011. Bars above and below
points represent the error bars of a sensitivity analysis where cases of unknown species daignosis were counted as either all P. falciparum or all P. vivax.
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anemia, pulmonary distress, altered consciousness, renal and
hepatic dysfunction, and circulatory collapse. Similar clinical
syndromes were observed in patients diagnosed with P. vivax
and treated in US hospitals during 1985–2011.
Although the reported rates of deaths and severe illness with
a diagnosis of P. vivax or P. falciparum were substantially lower
in travelers in the United States than those typically reported
from hospitals in malaria endemic areas [1], case fatality rates
amongst those with severe illness were comparable. Those
rates for P. falciparum and P. vivax were 9.3% and 1.3% for se-
vere illness, and among those with severe illness, 8.6% and 6.1%
case fatality, respectively. Although from a wide range of set-
tings with differing data, quality rates of severe illness with
these two diagnoses from hospitals in malaria endemic areas
widely ranged between approximately 10% and 30% of admis-
sions, and case fatality was typically between 5% and 15% [1].
The higher rates of severe illness observed in malaria endemic
areas can likely be attributed to higher probabilities of comor-
bidities and the multitude of other factors associated with the
poverty typical of most heavily malarious zones: endemic infec-
tions, geographic isolation and limited access to care, reluctance
to seek expensive care, poor nutrition, etc. Although comorbid-
ities can be present among international travelers, they typically
represent a relatively healthy and wealthy subpopulation. These
distinctions did not appear to impact the risk of death after the
onset of severe complications.
Vivax malaria has long been thought to be a relatively benign
condition, resulting in the occasional infarct or rupture of the
spleen. Like many reports from endemic areas over the past dec-
ade [1, 2, 20–27], the findings in this analysis of malaria cases
diagnosed and treated in the United States, especially in the pe-
riod 2008–2011, challenge the dogma of vivax malaria being
relatively harmless and not causing serious complications
such as severe anemia, respiratory distress, shock, altered
Figure 3. Proportion of all cases between 2008 and 2011 classified as severe, and the odds ratio for that classification in Plasmodium falciparum com-
pared with P. vivax, P. malariae, or P. ovale.
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consciousness, and other syndromes typically linked to falcipa-
rum malaria. Although a diagnosis of P. falciparum carried a
higher risk of severe illness relative to that of P. vivax (18.3%
vs 5.5%; P < .0001) during 2008–2011, the risk of severe illness
with vivax malaria should not be considered rare or limited to
injury to the spleen. Although less likely to run a malignant
course than P. falciparum, P. vivax also seems to be an inherent-
ly pernicious species capable of a fatal course in travelers and
residents of endemic areas alike.
As with all routine surveillance systems, limitations around
underreporting, data accuracy, and completeness exist in the
NMSS [28]. However, these limitations are not species specific.
It is possible that frontline clinicians define severity differently
or could have a differential perception of severity by species, but
severe illness and specific syndrome classification is completed
by the CDC based on the provided information. Although most
syndromes are not species specific, hyperparasitemia, defined as
>5%, is more relevant and common for P. falciparum. However,
the sensitivity analysis excluding hyperparasitemia alone as
qualifying as severe illness showed that the initial results were
robust. Although the inclusion of the use of parenteral artesu-
nate or quinidine alone without other manifestations in the
classification of severe illness could have overestimated the over-
all number of severe illness, this bias is not species specific and
is not likely to impact the comparative results.
Authoritative guidances from the US CDC and others have
recommended prophylactic antimalarials for prevention of
malaria in travelers [29–31]. This strategy mostly aims at killing
blood stages of the plasmodia as they emerge into the blood-
stream, and these drugs (doxycycline, chloroquine, and meflo-
quine) have no effect on the latent liver stages of P. vivax
responsible for repeated clinical attacks in the many months
(up to about two years) following primary infection. Suppres-
sive prophylaxis coupled with immediate post-travel presump-
tive anti-relapse therapy with primaquine is recommended for
persons departing from vivax and ovale endemic areas after a
period of extended exposure. In addition, the US CDC now rec-
ommends the use of primaquine for causal prophylaxis (a daily
dose of 30 mg (approximately 0.5 mg/kg for the average adult)
commencing with travel and ceasing seven days following travel
to vivax-endemic areas) [29], which may currently be the only
reliably effective chemoprophylaxis option for preventing both
primary and secondary attacks by P. vivax [32–34].
In summary, although 1985–2011 malaria surveillance data
affirms P. falciparum as the primary threat to travelers present-
ing in the United States both in terms of numbers of cases and
relative risk of severe illness and fatal outcomes, P. vivax also
constituted a significant clinical threat in all of these regards.
Thus, appropriate caution is warranted in dealing with the pre-
vention and treatment of vivax malaria. Although relatively very
few cases of infection by P. malariae and P. ovale have been
reported in the United States, the available data suggest these
species could pose risk of severe and fatal illnesses. Providers
recommending chemoprophylaxis or managing malaria in
Figure 4. Annual number of severe Plasmodium falciparum and Plasmodium vivax cases, and odds ratio for a classification of severe illness with diag-
nosis of P. falciparum compared with P. vivax among cases in the United States between 1985 and 2011. The odds ratio for 1985 and 1993 were 82.2 and
61.3, respectively, and are not plotted.
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travelers should consider no species of Plasmodium inherently
benign or clinically inconsequential. The clinical dichotomy of
falciparum versus non-falciparum malaria, as a prognostic clas-
sification that practically separates threatening from nonthreat-
ening malarias, ought to be abandoned as misleading and
potentially dangerous to the patient.
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